University and pharmaceutical firm create program to detect and better understand adverse drug reactions.
Humana and the University of Miami Leonard M. Miller School of Medicine are launching a program that will focus on detecting and understanding adverse drug reactions. Dubbed Pharmacovigilance Initiative, the program will be run by the University of Miami-Humana Health Services Research Center, a public-private partnership created in 2005 to focus on health services and health behavior research. The initiative is designed to protect the health and safety of the public, support better clinician decision-making through reporting on the comparative effectiveness of pharmaceuticals, and contribute to the ongoing dialogue on drug safety in Washington, D.C. "The reporting of adverse drug events to the FDA is strictly voluntary, and the recent drug recalls and stepped-up black box warnings would suggest something more needs to be done to protect patient safety," said Pascal J. Goldschmidt, M.D., senior VP for medical affairs and dean of the Miller School of Medicine. "This new initiative between the Miller School of Medicine and Humana is the right thing to do for the patient at the right time."